I started my YouTube channel from a hotel room in June 2019 after presenting my postdoc research at a physics conference in Oregon.
At the time, my only goal was to help people navigate the cryptoverse and avoid some of the mistakes I made as a younger investor.
I remember being genuinely excited when the channel reached its first 100 subscribers. It felt hard to imagine that many people would be interested in hearing my thoughts on markets.
Over the years, there have been plenty of successes, but also many mistakes that forced me to reassess my assumptions and become a more disciplined investor.
The truth is that this journey would not have been possible without all of you. Whether you've been here since the beginning or just recently found the channel, thank you for giving me the opportunity to do what I love every day.
Today, the channel reached 1 million subscribers.
I'm incredibly grateful for that, and I don't take it for granted.
Thank you for being part of the journey.
Retatrutide phase 3 obesity trial just came out and the results are genuinely insane:
- 28.3% bodyweight lost on 12mg over 80 weeks
- 70.3 pounds on avg. or 31.9 kg
- 45.3% of patients hit 30%+ weight loss (this is bariatric surgery territory)
- 30.3% weight loss (85 lbs) at 104 weeks in higher-BMI patients
- 65.3% of 12mg patients dropped below the obesity BMI threshold
- 19% loss on 4mg over 80 weeks (47.2 lbs) with fewer dropouts than placebo (4.1% vs 4.9%)
- significant drops in blood pressure, triglycerides, non-HDL cholesterol, waist circumference, and hsCRP
- no cardiac or liver signals
Retatrutide is going to completely overshadow tirzepatide and semaglutide, and take the throne as the best-selling drug of all time.